Published in Obesity and Diabetes Week, December 8th, 2003
The studies will be conducted in North America and Europe. The protocols for these studies have been approved by applicable regulatory agencies.
The target population includes youths failing oral hypoglycemic agents therapy as well as patients on multiple daily injections. The Oralin will be introduced in the treatment plan as a replacement for s.c. injections.
"While the number of patients with diabetes has been growing rapidly, the increase among teenagers is particularly alarming," said Anna Gluskin, CEO of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.